Targeted drugs score more wins

Posted 17 January 2019

Therapies targeting specific genetic mutations are more than twice as likely to receive regulatory approval, a new study claims. 

Three researchers working at the AbbVie Genomics Research Center in Chicago found drugs with "genetic support" had higher rates of approval compared to those which did not use genetic markers. 

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here